Strides, Akron JV files ANDA with Office of Generic Drugs

New Delhi, Aug 25 (UNI) Strides Arcolab Ltd today said the joint venture between Illinois-based Akorn and the company, Akorn-Strides, has submitted its tenth Abbreviated New Drug Application (ANDA) with the Office of Generic Drugs.

''We are delighted with the pace of filings through the JV with Akorn. We are confident of playing a significant role providing a strong pipeline and supplies to convert Akorn-Strides into a significant hospital player in the US,'' Strides Acrolab Executive Vice Chairman and Managing Director Arun Kumar.

The Akorn-Strides joint venture was formed in September 2004 as a result of the development, manufacturing, and marketing partnership between Akorn and the company. The first ANDA submission for the Akorn-Strides joint venture was filed in April 2006.

UNI CS RA RK2033